Regeneron (REGN) Announces Dupixent is Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. FDX
4. ABBV
5. META
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Regeneron (REGN) Announces Dupixent is Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis

Dupixent® (dupilumab) Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis

October 29, 2019 8:15 AM EDT

TARRYTOWN, N.Y. and PARIS, Oct. 29, 2019 /PRNewswire/ --  

First biologic approved in the European Union for adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP)

Dupixent now approved in the EU for three type 2 inflammatory diseases: severe CRSwNP, severe asthma and moderate-to-severe atopic dermatitis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved a new indication for Dupixent® (dupilumab) in chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe... More